López-Oliva María O, Rivas Begoña, Pérez-Fernández Elia, Ossorio Marta, Ros Silvia, Chica Carlos, Aguilar Ana, Bajo María-Auxiliadora, Escuin Fernando, Hidalgo Luis, Selgas Rafael, Jiménez Carlos
Department of Nephrology, University Hospital La Paz, IdiPAZ, Madrid, Spain,
Int Urol Nephrol. 2014 Apr;46(4):825-32. doi: 10.1007/s11255-013-0521-0. Epub 2013 Sep 8.
Kidney transplantation is the best option for the treatment of end-stage renal disease in terms of survival and quality of life. These results can be influenced by the pretransplant dialysis modality. The aim of this study was to evaluate whether the pretransplantation dialysis modality influences patient and allograft survival beyond 10 years and examine the potential risk factors associated with the outcomes.
We conducted an observational, retrospective, single-center clinical study that included 236 patients [118 undergoing peritoneal dialysis (PD) and 118 undergoing hemodialysis (HD)] who proceeded to transplantation during the period December 1990-2002. Donor and recipient data were collected from our hospital's clinical registries. The follow-up period extended to the patient's death, the loss of the allograft, or loss to follow-up. The end date of the study was set at March 2012.
In the multivariate analysis, the long-term patient survival rate was higher for the PD group than for the HD group [HR = 2.62 (1.01-6.8); p = 0.04]; however, the allograft survival rate was not significantly different between the two groups [HR = 0.68 (0.41-1.10); p = 0.12].
Pretransplantation dialysis modality is associated with long-term patient survival, with outcomes favoring peritoneal dialysis over hemodialysis. However, the pretransplant dialysis modality does not influence long-term graft loss risk.
就生存率和生活质量而言,肾移植是治疗终末期肾病的最佳选择。这些结果会受到移植前透析方式的影响。本研究的目的是评估移植前透析方式是否会影响患者及移植肾超过10年的生存率,并检查与这些结果相关的潜在风险因素。
我们进行了一项观察性、回顾性、单中心临床研究,纳入了1990年12月至2002年期间接受移植的236例患者[118例接受腹膜透析(PD),118例接受血液透析(HD)]。供体和受体数据从我院临床登记处收集。随访期延长至患者死亡、移植肾失功或失访。研究结束日期设定为2012年3月。
在多因素分析中,PD组的长期患者生存率高于HD组[风险比(HR)=2.62(1.01 - 6.8);p = 0.04];然而,两组间移植肾生存率无显著差异[HR = 0.68(0.41 - 1.10);p = 0.12]。
移植前透析方式与患者长期生存率相关,腹膜透析的结果优于血液透析。然而,移植前透析方式不影响长期移植肾失功风险。